title: Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.
abstract: Therapeutic approaches based on the actions of the incretin hormone GLP-1 have been widely established in the management of T2DM. Nevertheless, much less research has been aimed at elucidating the role of GLP-1 in lipid metabolism and in particular postprandial dyslipidemia. Exenatide and liraglutide are two GLP-1 receptor agonists which are currently available as subcutaneously administered treatment for T2DM but their chronic effects on postprandial lipaemia have not been well investigated. The aim of this study is to examine the effect of treatment with either liraglutide or exenatide for two weeks on postprandial lipaemia in obese subjects with T2DM. This study was a single-center, two-armed, randomized, controlled 2-week prospective intervention trial in 20 subjects with T2DM. Patients were randomized to receive either liraglutide or exenatide treatment and underwent a standardized meal tolerance test early in the morning after 10 h fast at baseline (visit 1, beginning of treatment) and after a two-week treatment period (visit 2). Exenatide and liraglutide both appear to be equally effective in lowering postprandial lipaemia after the first administration and after a two-week treatment. The mechanisms which lead to this phenomenon, which seem to be independent of gastric emptying, are yet to be studied.
authors.affiliation: Diabetes and Obesity Center, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Maria
authors.identifier: 0000-0003-2960-9795
authors.initials: M
authors.lastname: Voukali
authors.affiliation: Biochemistry Laboratory, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Irene
authors.initials: I
authors.lastname: Kastrinelli
authors.affiliation: Biochemistry Laboratory, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Sapfo
authors.initials: S
authors.lastname: Stragalinou
authors.affiliation: Diabetes and Obesity Center, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Dimitra
authors.identifier: 0000-0003-4577-5152
authors.initials: D
authors.lastname: Tasiopoulou
authors.affiliation: Biochemistry Laboratory, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Pinelopi
authors.initials: P
authors.lastname: Paraskevopoulou
authors.affiliation: 1st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, Athens University Medical School, 17 Agiou Thoma Street, 115 27 Athens, Greece.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Katsilambros
authors.affiliation: 1st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, Athens University Medical School, 17 Agiou Thoma Street, 115 27 Athens, Greece.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Kokkinos
authors.affiliation: 1st Department of Propaedeutic and Internal Medicine, Laiko General Hospital, Athens University Medical School, 17 Agiou Thoma Street, 115 27 Athens, Greece.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Tentolouris
authors.affiliation: Diabetes and Obesity Center, Konstantopouleio Hospital, 3-5 Agias Olgas Street, Nea Ionia, 14233 Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Ioannidis
mesh_terms: D000328:Adult; D000368:Aged; D048909:Diabetes Complications / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D019518:Postprandial Period; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide